Cellectar Biosciences, Inc. (CLRB)
1.78
-0.09
(-4.81%)
USD |
NASDAQ |
Oct 02, 16:00
1.82
+0.04
(+2.25%)
After-Hours: 20:00
Cellectar Biosciences Enterprise Value : -17.77M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -17.77M |
| October 01, 2026 | -17.03M |
| September 30, 2026 | -17.28M |
| September 29, 2026 | -17.44M |
| September 28, 2026 | -17.36M |
| September 25, 2026 | -17.61M |
| September 24, 2026 | -15.34M |
| September 23, 2026 | -15.22M |
| September 22, 2026 | -14.06M |
| September 21, 2026 | -13.07M |
| September 18, 2026 | -12.82M |
| September 17, 2026 | -12.66M |
| September 16, 2026 | -13.07M |
| September 15, 2026 | -13.32M |
| September 14, 2026 | -13.40M |
| September 11, 2026 | -13.40M |
| September 10, 2026 | -12.90M |
| September 09, 2026 | -12.95M |
| September 08, 2026 | -12.57M |
| September 04, 2026 | -12.90M |
| September 03, 2026 | -13.07M |
| September 02, 2026 | -12.41M |
| September 01, 2026 | -12.16M |
| August 31, 2026 | -11.75M |
| August 28, 2026 | -11.58M |
| Date | Value |
|---|---|
| August 27, 2026 | -11.50M |
| August 26, 2026 | -11.50M |
| August 25, 2026 | -11.50M |
| August 24, 2026 | -11.67M |
| August 21, 2026 | -11.09M |
| August 20, 2026 | -11.09M |
| August 19, 2026 | -10.84M |
| August 18, 2026 | -11.09M |
| August 17, 2026 | -11.34M |
| August 14, 2026 | -11.01M |
| August 13, 2026 | -12.00M |
| August 12, 2026 | -11.01M |
| August 11, 2026 | -10.68M |
| August 10, 2026 | -11.01M |
| August 07, 2026 | -11.25M |
| August 06, 2026 | -11.67M |
| August 05, 2026 | -11.67M |
| August 04, 2026 | -11.34M |
| August 03, 2026 | -10.51M |
| July 31, 2026 | -11.25M |
| July 30, 2026 | -11.58M |
| July 29, 2026 | -12.00M |
| July 28, 2026 | -11.83M |
| July 27, 2026 | -12.49M |
| July 24, 2026 | -12.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.931M |
| Total Expenses (Quarterly) | 6.931M |
| EPS Diluted (Quarterly) | -0.5666 |
| Earnings Yield | -255.9% |
| Normalized Earnings Yield | -263.42 |